[轉載]香港研究：BNT疫苗產生的抗體是科興10倍

https://www.france24.com/en/live-news/20210716-biontech-produces-10-times-more-antibodies-than-china-s-sinovac-study

(以下使用機器翻譯，可能存在錯誤，請以原文為準)

发布： 16/07/2021 - 08:02

香港（法新社）

香港的一项研究显示，接种 BioNTech 冠状病毒疫苗的人的抗体量是接种中国华兴疫苗的人的十倍，这增加了有关不同刺戳有效性的数据。

香港大学（HKU）的研究基于对 1,442 名医护人员的研究，于周四发表在《柳叶刀微生物》上。

研究人员表示，抗体并不是衡量疫苗在对抗特定疾病方面是否成功的唯一标准。

但他们警告说，“我们研究中发现的中和抗体浓度的差异可能会转化为疫苗有效性的显着差异”。

那些接受 Sinovac 治疗的患者的抗体水平与在感染并成功战胜疾病的患者身上看到的抗体水平“相似或更低”。

该研究增加了越来越多的证据，表明使用开创性 mRNA 技术（如 BioNTech 和 Moderna）的疫苗比通过更传统方法（如使用灭活的病毒部分）开发的疫苗提供了更好的针对冠状病毒及其变体的保护。

传统疫苗的生产成本更低，运输和储存也更简单，这使其成为在欠富裕国家抗击大流行的重要工具。

- '许多生命仍然得救' -

该报告的作者之一、流行病学家本考林说，如果没有其他选择，人们仍然应该接种科兴疫苗，因为有些保护总比没有好。

#照片1
“不要让完美成为好人的敌人，”他告诉法新社。

“显然，去接种灭活疫苗比等待不接种要好，”他补充说。

“灭活疫苗挽救了许多人的生命。”

研究人员表示，他们的数据表明，可能需要采取“替代策略”，例如更早地注射加强针，以加强对那些接受过科诺兴的人的保护。

考林说，何时给予加强注射将是他们正在进行的研究的下一阶段。

他说：“优先事项是为接受 Sinovac 的人提供助推器，而为最初接受 BioNTech 的人提供助推器可能不那么紧急。”

- 政治 -

自 2003 年在中国南部爆发的非典疫情席卷香港以来，香港一直是研究冠状病毒的世界领先者。

该市目前提供德国制造的 BioNTech 镜头和 Sinovac。

尽管供应充足，但吸收速度缓慢，该市 750 万居民中只有 28% 的人接种了两次疫苗。

到目前为止，已经注射了大约 260 万剂 BioNTech 疫苗，而 Sinovac 注射了 180 万剂。

两年前，中国政府镇压香港的异议人士，以应对大规模且经常是暴力的民主抗议活动，因此该计划的推出已卷入香港的狂热政治之中。

#照片2
在疫苗接种运动开始时，香港亲北京的领导人非常明显且几乎一致选择了科兴。

一家推荐 BioNTech 而不是 Sinovac 的医生诊所被踢出了该市的疫苗接种计划。

该市许多领先的流行病学家都选择了 BioNTech，并公开表示这是他们的首选。

**************************
BioNTech produces 10 times more antibodies than China's Sinovac: study

Hong Kong (AFP)

People who received BioNTech's coronavirus vaccine had ten times the amount of antibodies than those given China's Sinovac, a Hong Kong study has shown, adding to growing data on different jabs' effectiveness.

The University of Hong Kong (HKU) research, based on a study of 1,442 healthcare workers, was published in Lancet Microbe on Thursday.

Researchers said antibodies are not the only measure of a vaccine's success at fighting a particular disease.

But they warned that "the difference in concentrations of neutralising antibodies identified in our study could translate into substantial differences in vaccine effectiveness".

Those who received Sinovac had "similar or lower" levels of antibodies to those seen in patients who caught and successfully fought off the disease.

The study adds to the growing body of evidence that vaccines using pioneering mRNA technology -- such as BioNTech and Moderna -- offer better protection against the coronavirus and its variants that those developed by more traditional methods such as using inactivated virus parts.

Traditional vaccines are cheaper to produce and less complicated to transport and store, making them a vital tool for fighting the pandemic in less wealthy countries.

- 'Many lives still saved' -

Epidemiologist Ben Cowling, one of the report's authors, said people should still get vaccinated with Sinovac if there was no other option because some protection was always better than none.

#photo1
"Don't let the perfect be the enemy of the good," he told AFP.

"It is clearly better to go and get vaccinated with an inactivated vaccine than to wait and not get vaccinated," he added.

"Many, many lives have been saved by the inactivated vaccine."

The researchers said their data suggested "alternative strategies" such as earlier booster shots might be needed to increase protection for those who have received Sinovac.

Cowling said when to give booster shots would be the next phase of their ongoing studies.

"The priority would be boosters for people who received Sinovac while boosters for people who initially received BioNTech might not be so urgent," he said.

- Politics -

Hong Kong has been a world leader in studying coronaviruses ever since a SARS outbreak which began in southern China swept through the city in 2003.

The city currently offers both German-made BioNTech shots and Sinovac.

Despite ample supplies, take-up has been slow, with only 28 percent of the city's 7.5 million residents fully vaccinated with two shots.

So far some 2.6 million BioNTech doses have been administered compared to 1.8 million Sinovac shots.

The rollout has been caught up in Hong Kong's febrile politics, as China cracks down on dissent in the city in response to huge and often violent democracy protests two years ago.

#photo2
At the start of the vaccination campaign Hong Kong's pro-Beijing leaders very visibly and near unanimously opted for Sinovac.

One doctor's clinic that recommended BioNTech over Sinovac was kicked out of the city's vaccination programme.

Many of the city's leading epidemiologists have gone with BioNTech, and said publicly that it is their preferred shot.